Protein Kinase Inhibitors: all 15,766 studies that test it

Page 145 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy VolunteersCompletedNCT00658554Phase 1
• Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate CancerStatus unknownNCT00657982Phase 2
• Extension Program for Bay 43-9006CompletedNCT00657254Phase 2
• APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)TerminatedNCT00657137Phase 2
• Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular EdemaCompletedNCT00656643Phase 2
• Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
• Dasatinib in Resectable Malignant Pleural MesotheliomaCompletedNCT00652574Phase 1
• A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced MalignanciesTerminatedNCT00652158Phase 1
• A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) GenotypeCompletedNCT00651638Phase 1
• A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.TerminatedNCT00651365Phase 1
• Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast CancerCompletedNCT00650910Phase 1
• A Study of ARRY-380 in Patients With Advanced HER2+ CancerCompletedNCT00650572Phase 1
• Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast CancerCompletedNCT00645177Phase 2
• A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00642148Phase 2
• Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic MalignanciesCompletedNCT00642031Phase 1
• Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal CancerCompletedNCT00640471Phase 3
• Tarceva Italian Lung Optimization tRialStatus unknownNCT00637910Phase 3
• A Study of ARRY-334543 in Patients With Advanced CancerCompletedNCT00637702Phase 1
• Study of AZD8931 in Patients With Advanced Solid MalignanciesCompletedNCT00637039Phase 1
• Ph II Early BC Pre-Surgical Biologic StudyCompletedNCT00637026Phase 2
• Everolimus (RAD001) in Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT00636922Phase 1
• Open-Label Extension of Other SZ1839 (Iressa) TrialsCompletedNCT00635973Phase 3
• Open Label Trial to Assess Iressa in Prostate Cancer PatientsCompletedNCT00635856Phase 2
• Phase I Study of Vorinostat and Sorafenib in Advanced CancerCompletedNCT00635791Phase 1
• ABI-009 Trial in Patients With Advanced Non-hematologic MalignanciesCompletedNCT00635284Phase 1
• Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by SurgeryCompletedNCT00634725Phase 3
• Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesCompletedNCT00633789Phase 2
• Study of Apatinib as an Inhibitor of Tumor AngiogenesisStatus unknownNCT00633490Phase 1
• Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) InhibitorCompletedNCT00633295Phase 2
• IRESSA™ (Gefitinib) in Breast Cancer PatientsCompletedNCT00632723Phase 2
• Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric CancerCompletedNCT00632268Phase 2
• Clinical Trial of Sutent to Treat Metastatic MelanomaCompletedNCT00631618Phase 2
• Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate CancerCompletedNCT00631527Phase 1
• A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With MyelofibrosisCompletedNCT00631462Phase 1
• Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)WithdrawnNCT00627835Phase 1
• Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney CancerStatus unknownNCT00626509Phase 2
• Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic MelanomaCompletedNCT00623402Phase 2
• Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.TerminatedNCT00622479Phase 1
• A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00622258Phase 1
• Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid TumoursCompletedNCT00621725Phase 1
• Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer PatientsCompletedNCT00621361Phase 1
• Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy SubjectsCompletedNCT00621101Phase 1
• A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast CancerCompletedNCT00620594Phase 1
• Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung CancerCompletedNCT00620347Phase 2
• Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC IIIStatus unknownNCT00620269Phase 2
• Study of Sorafenib and Docetaxel in Metastatic Prostate CancerCompletedNCT00619996Phase 2
• Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00619541Phase 2
• A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid TumorsCompletedNCT00619424Phase 1
• Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell CarcinomaCompletedNCT00619268Phase 2
• Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00618501Phase 2
• TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)TerminatedNCT00618384Phase 2
• Everolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00618345Phase 2
• A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered TogetherCompletedNCT00618124Phase 1
• Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma PatientsCompletedNCT00617253Phase 2
• Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung CancerStatus unknownNCT00616499Phase 2
• Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IVCompletedNCT00615758Phase 2
• Safety, Tolerability, and Efficacy of AEB071 in the Treatment of UveitisCompletedNCT00615693Phase 2
• Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast CancerWithdrawnNCT00615524Phase 2
• A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid TumorsCompletedNCT00615446Phase 1
• Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast CancerCompletedNCT00614978Phase 1
• Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung CancerStatus unknownNCT00614809Phase 2
• Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic CancerCompletedNCT00614653Phase 1
• Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant GliomasCompletedNCT00613223Phase 1
• Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid TumorsCompletedNCT00613145Phase 1
• Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant GliomaCompletedNCT00613054Phase 1
• A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612703Phase 1
• Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell TransplantationCompletedNCT00612274Early Phase 1
• A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612209Phase 1
• PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced MalignanciesCompletedNCT00611793Phase 1
• Ph I SU011248 + Irinotecan in Treatment of Pts w MGCompletedNCT00611728Phase 1
• Bevacizumab and Temsirolimus in Patients With Advanced MalignancyCompletedNCT00610493Phase 1
• A Study of Radiation With Sorafenib in Advanced CancerCompletedNCT00610246Phase 1
• Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer PatientsCompletedNCT00610194Phase 1
• Ph I Dasatinib + Erlotinib in Recurrent MGCompletedNCT00609999Phase 1
• Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the BoneCompletedNCT00609934Phase 1/2
• A Phase 1 Study of ARQ 197 in Patients With Solid TumorsCompletedNCT00609921Phase 1
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast CancerTerminatedNCT00607438Phase 2
• Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid TumorsTerminatedNCT00607399Phase 1
• Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid TumorsTerminatedNCT00606879Phase 1
• MRI Study of BAY 43-9006 in Metastatic Renal Cell CarcinomaCompletedNCT00606866Phase 3
• Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid TumorsCompletedNCT00606125Phase 1
• Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT00605618Phase 1/2
• CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal ImpairmentCompletedNCT00604357Phase 3
• Phase I Study of OSI-930 and Erlotinib in Cancer TumorsCompletedNCT00603356Phase 1
• Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250CompletedNCT00602862Not applicable
• Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by SurgeryCompletedNCT00601913Early Phase 1
• Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00601614Phase 1
• Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach CancerCompletedNCT00601510Phase 1
• Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00600587Phase 2
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedNCT00600496Phase 1
• A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast CancerCompletedNCT00600275Phase 1/2
• To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult MalesCompletedNCT00599612Phase 1
• Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- TarcevaCompletedNCT00598156Phase 3
• A Phase I/Expansion Study of DasatinibTerminatedNCT00598091Phase 1
• Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow upCompletedNCT00596557Phase 4
• Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric CancerTerminatedNCT00595985Phase 2
• A Phase 1 Study of XL019 in Adults With Polycythemia VeraTerminatedNCT00595829Phase 1
• Phase I/II Combination With Irinotecan- ErbituxCompletedNCT00594984Phase 1/2
• A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid LeukemiaWithdrawnNCT00594555Phase 2

← Protein Kinase Inhibitors overview